Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

Teresa Calimeri, MD PhD, Daniele Caracciolo, MD, Nicola Amodio, PhD, Mehmet Kemal Samur, PhD, Marzia Leotta, MD, Mariateresa Fulciniti, PhD, Marco Rossi, MD, Stephane Minvielle, Herve Avet-Loiseau, Pierosandro Tagliaferri, MD, Masood Shammas, PhD, Kenneth C. Anderson, Pierfrancesco Tassone, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3417.

https://doi.org/10.1182/blood.V124.21.3417.3417

Published: 2014

Journal Articles

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

Maria Teresa Di Martino, PhD, Annamaria Gullà, MD, Maria Eugenia Gallo Cantafio, Emanuela Altomare, PhD, Nicola Amodio, PhD, Emanuela Leone, PhD, Santo Giovanni Lio, Eugenio Morelli, MD, Daniele Caracciolo, MD, Cirino Botta, MD, Antonino Neri, MD, Niels M Frandsen, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 3166.

https://doi.org/10.1182/blood.V122.21.3166.3166

Published: 2013

Journal Articles

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Alessandro Rambaldi, MD, Cristina Boschini, Federica Delaini, BiolSC, Elena Oldani, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Angela Gueli, MD, Alberto De Crescenzo, MD, Roberto Passera, PhD, Liliana Devizzi, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2012) 120 (21): 1553.

https://doi.org/10.1182/blood.V120.21.1553.1553

Published: 2012

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Silvia Govi, MD, Caterina Patti, MD, Markus Raderer, MD, Alessandro Andriani, MD, Daniele Caracciolo, MD, Anna Guidetti, MD, Fiorella Ilariucci, MD, Stefano Luminari, MD, Antonino Mulè, MD, Edi Viale, MD, Paolo Giorgio Arcidiacono, MD, Maurilio Ponzoni, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 958.

https://doi.org/10.1182/blood.V118.21.958.958

Published: 2011

Journal Articles

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

Blood (2009) 114 (22): 519.

https://doi.org/10.1182/blood.V114.22.519.519

Published: 2009

Journal Articles

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.

Marco Ruella, MD, Irene Ricca, MD, Angela Gueli, MD, Daniela Gottardi, MD, Daniele Caracciolo, MD, Luciana Bergui, MD, Paolo Gavarotti, MD, Alberto De Crescenzo, MD, Lucia Farina, Paolo Corradini, MD, Corrado Tarella, MD

Blood (2009) 114 (22): 3434.

https://doi.org/10.1182/blood.V114.22.3434.3434

Published: 2009

Journal Articles

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Roberto Crocchiolo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Michele Magni, MD, Mario Boccadoro, MD, Fabio Ciceri, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD

Blood (2007) 110 (11): 1889.

https://doi.org/10.1182/blood.V110.11.1889.1889

Published: 2007

Journal Articles

The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.

Irene Ricca, MD, Alberto Rocci, MD, Marco Ruella, MD, Manuela Zanni, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Mario Boccadoro, MD, Dario Ferrero, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 1672.

https://doi.org/10.1182/blood.V110.11.1672.1672

Published: 2007

Journal Articles

Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.

Angela Gueli, MD, Daniele Caracciolo, MD, Manuela Zanni, MD, Luciana Bergui, MD, Paolo Gavarotti, MD, Marco Ladetto, MD, Andrea Filippi, MD, Roberto Passera, PhD, Mario Boccadoro, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 1373.

https://doi.org/10.1182/blood.V110.11.1373.1373

Published: 2007

Journal Articles

Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.

Alberto Rocci, MD, Marco Ruella, MD, Irene Ricca, MD, Cristiana Carniti, PhD, Manuela Zanni, MD, Chiara Lobetti Bodoni, MD, Marco Ladetto, MD, Daniele Caracciolo, MD, Mario Boccadoro, MD, Paolo Corradini, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 3025.

https://doi.org/10.1182/blood.V110.11.3025.3025

Published: 2007

Journal Articles

High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ).

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Alessandra Pescarollo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Michele Magni, MD, Liliana Devizzi, MD, Mario Boccadoro, MD, Marco Bregni, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD

Blood (2005) 106 (11): 2068.

https://doi.org/10.1182/blood.V106.11.2068.2068

Published: 2005

Journal Articles

Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients.

Davide Bono, MD, Manuela Zanni, MD, Irene Ricca, MD, Daniele Caracciolo, MD, Elisa Dama, MD, Corrado Magnani, MD, Paolo Gavarotti, MD, Luciana Bergui, MD, Alessandra Cuttica, MD, Marco Ladetto, MD, Mario Boccadoro, MD, Dario Ferrero, MD, Corrado Tarella, MD

Blood (2004) 104 (11): 2248.

https://doi.org/10.1182/blood.V104.11.2248.2248

Published: 2004

Journal Articles

Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Irene Ricca, MD, Daniela Drandi, PhD, Alberto Rocci, MD, Mara Compagno, PhD, Roberto Francese, PhD, Barbara Mantoan, PhD, Claudia Castellino, MD, Francesca Ficara, MD, Sonia Vallet, MDD, Maria Dell’Aquila, PhD, Loredana Santo, MD, Daniele Caracciolo, MD, Luciana Bergui, MD, Andrea Gallamini, MD, Mario Bazzan, MD, Carlo Marinone, MD, Mario Boccadoro, MD, Corrado Tarella, MD, Marco Ladetto, MD

Blood (2004) 104 (11): 4768.

https://doi.org/10.1182/blood.V104.11.4768.4768

Published: 2004

Journal Articles

Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.

Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Alessandra Pescarollo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Michele Magni, MD, Liliana Devizzi, MD, Mario Boccadoro, MD, Ignazio Majolino, MD, Marco Bregni, MD, Andrea Gallamini, MD, Salvo Mirto, MD, Marco Ladetto, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2004) 104 (11): 891.

https://doi.org/10.1182/blood.V104.11.891.891

Published: 2004

Journal Articles

Telomere Length of Hematopoietic Cells in Long-Term Post-Autograft Survivors: No Evidence of Accelerated Replicative Cell Senescence Despite the Persistent Reduction of Both Committed and Immature Progenitor Cell Compartments.

Alberto Rocci, MD, Irene Ricca, MD, Chiara Della Casa, MD, Paolo Longoni, PhD, Mara Compagno, PhD, Maurizio Battistelli, PhD, Roberto Francese, PhD, Federica De Marco, MD, Daniele Caracciolo, MD, Mario Boccadoro, MD, Dario Ferrero, MD, Marco Ladetto, MD, Carmelo Carlo-Stella, MD, Corrado Tarella, MD

Blood (2004) 104 (11): 4123.

https://doi.org/10.1182/blood.V104.11.4123.4123

Published: 2004

NARROW

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.

Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.

Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.

Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients.

Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.

Telomere Length of Hematopoietic Cells in Long-Term Post-Autograft Survivors: No Evidence of Accelerated Replicative Cell Senescence Despite the Persistent Reduction of Both Committed and Immature Progenitor Cell Compartments.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only